Altea Therapeutics Appoints Senior R&D Executive Dr. David J. Enscore to Lead Product Development; Formerly of ALZA, Focal and Spherics with over 20 Years Product Development Success.Business Editors/Health/Medical Writers TUCKER, Ga.--(BUSINESS WIRE)--Dec. 11, 2003 Altea Therapeutics has appointed David J David J. Haskins (b. April 24, 1957, in Northampton, England) is a British alternative rock musician. He was the bassist for the seminal gothic rock band Bauhaus. Life and work . Enscore, PhD, as Senior Vice President for Product Research & Development. Dr. Enscore is responsible for leading all of the Company's pharmaceutical product research and development activities. The Company's lead clinical products are a daily insulin skin patch skin patch, transdermal patch, or transdermal delivery system, adhesive patch used to deliver a controlled dose of a drug through the skin over a period of time. for treating individuals with diabetes and a hydromorphone skin patch for the controllable management of severe acute and chronic pain. David Enscore has had an extensive career in the development of novel therapeutic products. He was previously at ALZA as Executive Director, Transdermal Product Development where he managed the development of four commercial controlled release pharmaceuticals, including NICODERM CQ (Transdermal Nicotine). More recently he was Vice President for Research & Development at Focal, Inc., responsible for the definition, development and market introduction of two surgical sealant Sealant A thin plastic substance that is painted over teeth as an anti-cavity measure to seal out food particles and acids produced by bacteria. Mentioned in: Tooth Decay sealant see bone sealant. products: FocalSeal-L and FocalSeal-S. He joins Altea Therapeutics from Spherics spher·ics 1 n. (used with a sing. verb) 1. Spherical geometry. 2. Spherical trigonometry. , Inc., a drug delivery company based in Lincoln, RI, where was President and Head of Research & Development. Dr. Enscore is an Inventor on 24 U.S. patents in drug delivery and medical devices. "David's appointment will strengthen both our pharmaceutical development capabilities and our project management needs as we transition from a technology-based company to one developing high-value pharmaceutical products" said Eric Tomlinson, D.Sc., Ph.D., the Company's Chief Executive Officer." He continued, "The advanced skin patch technology of Altea Therapeutics holds great promise for improving drug and vaccine efficacy Vaccine efficacy is defined as the reduction in the incidence of a disease among people who have received a vaccine compared to the incidence in unvaccinated people. The efficacy of a new vaccine is measured in phase III clinical trials by giving one group of people a vaccine and and safety as well as patient compliance. It offers a painless alternative to needle injections while providing controllable drug delivery," said Dr. Enscore. "I am thrilled to be joining my new colleagues as we seek to bring novel drug and vaccine products, with corporate partners, to the market place." About Altea Therapeutics Altea Therapeutics is a private Company developing innovative medicines in collaboration with the pharmaceutical and biotechnology industry. The Company uses its proprietary PassPort(TM) system to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines from a skin patch, to improve therapeutic utility and eliminate the need for invasive and painful needle injections. The Company is currently conducting Phase 1/2 clinical trials in the U.S. for AT1391, a daily skin patch to achieve continuous basal levels of insulin for patients with diabetes, and Phase 1 clinical trials phase 1 clinical trial Phase 1 study. See Phase study. for AT1022, a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate opiate /opi·ate/ (o´pe-it) 1. any drug derived from opium. 2. hypnotic (2). o·pi·ate n. 1. for the management of severe pain. Founded in 1998, Altea Therapeutics completed its Series B equity financing Equity Financing The act of raising money for company activities by selling common or preferred stock to individual or institutional investors. In return for the money paid, shareholders receive ownership interests in the corporation. of $17 million in November 2002 with Domain Associates, Venrock Associates and vSpring Capital vSpring Capital is an early-stage venture capital firm located in Salt Lake City, Utah. The fund currently manages approximately $200M and investing out of its second fund. as new investors. Please visit www.alteatherapeutics.com for further information. NOTE: PassPort(TM) is a trademark of Altea Therapeutics Corporation. Any other trademarks referred to belong to their respective owners. The statements in this press release regarding the products of Altea Therapeutics in development, product development plans, and projected financial results, are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Altea Therapeutics ability to complete the design, development, and manufacturing process development of its products, manufacture and commercialize its products, obtain product and manufacturing approvals from regulatory agencies regulatory agency Independent government commission charged by the legislature with setting and enforcing standards for specific industries in the private sector. The concept was invented by the U.S. , manage its growth and expenses, finance its activities and operations, as well as marketplace acceptance of Altea Therapeutics products. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion